Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG

Open source

DOI: 10.1080/14796694.2025.2592527
Published: 2025 Dec
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2592527,
  title = {Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.},
  author = {Ahn MJ and Delmonte A and Ghosh S and Hochmair M and Yang TY and Yang JC and Han JY and Hansen KH and Wu Y and Wan Y and Lin HM and Kretz J and Hupf B and Kurec AM and Churchill EN and Fram RJ and Cabasag CJ and Goriya V and Zhao Y and Campelo MRG},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2025.2592527},
  url = {https://doi.org/10.1080/14796694.2025.2592527}
}

RIS

TY  - JOUR
TI  - Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
AU  - Ahn MJ
AU  - Delmonte A
AU  - Ghosh S
AU  - Hochmair M
AU  - Yang TY
AU  - Yang JC
AU  - Han JY
AU  - Hansen KH
AU  - Wu Y
AU  - Wan Y
AU  - Lin HM
AU  - Kretz J
AU  - Hupf B
AU  - Kurec AM
AU  - Churchill EN
AU  - Fram RJ
AU  - Cabasag CJ
AU  - Goriya V
AU  - Zhao Y
AU  - Campelo MRG
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2025.2592527
UR  - https://doi.org/10.1080/14796694.2025.2592527
ER  -

APA

MJ, A., A, D., S, G., M, H., TY, Y., JC, Y., JY, H., KH, H., Y, W., Y, W., HM, L., J, K., B, H., AM, K., EN, C., RJ, F., CJ, C., V, G., Y, Z., & MRG, C. (2025). Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2592527

Source records

pubmed · retrieved 2026-09-25T22:11:52.955Z